CURRENT POSSIBILITIES OF DRUG THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER

The advent of a variety of new drugs to treat castration-resistant prostate cancer (CRPC), which have demonstrated their efficacy in increasing overall and progression-free survival, has considerably enhanced treatment possibilities in this category of patients. The standard treatment of metastatic CRPC (mCRPC) remains to be first-line chemotherapy with docetaxel 75 mg/m2 in combination with prednisolone 10 mg/day every 3 weeks. The new drugs also available in Russia are cabazitaxel and abiraterone acetate, which are approved for second-line treatment in mCRPC patients treated with docetaxel. The optimum sequence of therapy and the time of its use in view of the heterogeneity of a CRPC patient population remain open.